Skip to main content

Table 3 Summary of expert opinion on MCI

From: Souvenaid in the management of mild cognitive impairment: an expert consensus opinion

• Early diagnosis of MCI requires the use of suitable neuropsychological tests combined with a careful clinical history. Physicians should explore the clinical history because it provides important information about the changes in individual patients, which may alert them to the emerging cognitive impairment even when an objective screening test is normal.
• A multimodal approach is recommended; dietary and nutritional interventions should be considered alongside individualized lifestyle modifications. Pharmacologic therapy, except for the treatment of depression or other neuropsychiatric symptoms, is usually not appropriate for patients diagnosed with MCI.
• Although single-agent nutritional supplements have failed to produce cognitive benefits for patients with MCI, a broader nutritional approach warrants consideration.
• Evidence from randomized controlled trials suggests that Souvenaid should be considered as a management option for patients with early AD, including MCI.
• Souvenaid should be considered as an option for patients with a diagnosis of MCI due to AD (prodromal AD) or mild AD dementia. Souvenaid is not recommended for patients with moderate or advanced AD dementia
• Patients with MCI should take Souvenaid for 2 years or longer if there is evidence of continuing benefit.